Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 3/2015

01-12-2015 | Original Paper

Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway

Authors: Alexandros Giakoustidis, Satvinder Mudan, Thorsten Hagemann

Published in: Cancer Microenvironment | Issue 3/2015

Login to get access

Abstract

The tumour microenvironment (TME) represents a dynamic network that plays an important role in tumour initiation, proliferation, growth, and metastasis. Cell behaviour may be regulated by interplay of molecular interactions involving positive and negative reinforcement as well as a high level of cross-talk, which determines this system. Additionally, cancer involves cell proliferation, its malignancy defined by the tumour’s ability to break down normal tissue architecture and by a dynamic process of invasion and metastasis. The metastatic cascade is regulated by a chain of molecular steps which triggers the progression of the developing cancer cell in the primary tumour into a number of transformations, leading to invasion and proceeding to metastases. Tumour-associated macrophages (TAMs) play a key-role in the progression from inflammatory conditions to cancer; TAMs are also capable of infiltrating the tumour microenvironment. Furthermore, myeloid-derived suppressor cells (MDSCs), a population of inhibitory immune cells, have been reported to increase in various cancer types, although characterising human MDSCs remains difficult, as their phenotype is quite variable. The future of cancer treatment is likely to involve creating more drugs that target these elements as well as others. An overview of the tumour’s microenvironment is, therefore, presented in this paper, focusing on the metastatic pathways of primary colorectal cancer to the liver.
Literature
1.
2.
Witz IP, Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242(1):1–10PubMedCrossRef
3.
4.
Ideker T, Galitski T, Hood L (2001) A new approach to decoding life: systems biology. Annu Rev Genom Hum Genet 2:343–372CrossRef
5.
Ingber DE, Tensegrity II (2003) How structural networks influence cellular information processing networks. J Cell Sci 116:1397–1408PubMedCrossRef
6.
Huang S, Eichler G, Bar-Yam Y, Ingber DE (2005) Cell fates as high-dimensional attractor states of a complex gene regulatory network. Phys Rev Lett 94:128701PubMedCrossRef
7.
Huang S, Ingber DE (1999) The structural and mechanical complexity of cell-growth control. Nat Cell Biol 1:E131–E138PubMedCrossRef
8.
Ingber DE (2002) Cancer as a disease of epithelial–mesenchymal interactions and extracellular matrix regulation. Differentiation 70:547–560PubMedCrossRef
9.
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef
10.
Nawshad A, LaGamba D, Hay ED (2005) Microarray analysis of gene expression during epithelial–mesenchymal transformation. Dev Dyn 234:132–142PubMedCrossRef
11.
12.
Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M, D’Angelica MI, Kemeny NE (2012) Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 29(7):821–839PubMedCrossRef
13.
Rasanen K, Vaheri A (2010) Activation of fibroblasts in cancer stroma. Exp Cell Res 316(17):2713–2722PubMedCrossRef
14.
Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263–266PubMedCrossRef
15.
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–265PubMedCrossRef
16.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444PubMedCrossRef
17.
18.
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW (2010) Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 184:702–712PubMedPubMedCentralCrossRef
19.
Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, Rosol TJ, Fernandez S, Huang K, Leone G et al (2010) An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 70:1323–1333PubMedPubMedCentralCrossRef
20.
Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(Pt 23):5591–5596PubMedCrossRef
21.
Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104:2224–2234PubMedCrossRef
22.
Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE (2002) Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxiaregulated cancer gene therapy. J Pathol 196:204–212PubMedCrossRef
23.
White JR, Harris RA, Lee SR, Craigon MH, Binley K, Price T, Beard GL, Mundy CR, Naylor S (2004) Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 83:1–8PubMedCrossRef
24.
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW (2010) Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 184:702–712PubMedPubMedCentralCrossRef
25.
Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, Rosol TJ, Fernandez S, Huang K, Leone G et al (2010) An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 70:1323–1333PubMedPubMedCentralCrossRef
26.
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889–896PubMedCrossRef
27.
28.
29.
Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, Idoyaga J, Cheong C, Yao KH, Niec RE et al (2012) Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 209:1153–1165PubMedPubMedCentralCrossRef
30.
Qin JZ, Upadhyay V, Prabhakar B, Maker AV (2013) Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med 11:70PubMedPubMedCentralCrossRef
31.
Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, Idoyaga J, Cheong C, Yao KH, Niec RE et al (2012) Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 209:1153–1165PubMedPubMedCentralCrossRef
32.
Satpathy AT, Kc W, Albring JC, Edelson BT, Kretzer NM, Bhattacharya D, Murphy TL, Murphy KM (2012) Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med 209:1135–1152PubMedPubMedCentralCrossRef
33.
Penna C, Nordlinger B (2002) Surgery of liver metastases from colorectal cancer: new promises. Br Med Bull 64:127–140PubMedCrossRef
34.
35.
Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P (2013) The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 73(7):2031–2043PubMedCrossRef
36.
Leupold JH, Asangani I, Maurer GD et al (2007) Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res 5:485–496PubMedCrossRef
37.
Karkkainen MJ, Makinen T, Alitalo K (2002) Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 4:E2–E5PubMedCrossRef
38.
Meijer J, Zeelenberg IS, Sipos B et al (2006) The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 66:9576–9582PubMedCrossRef
39.
Weiss L (1989) Biomechanical destruction of cancer cells in skeletal muscle: a rate-regulator for hematogenous metastasis. Clin Exp Metastasis 7:483–491PubMedCrossRef
40.
Wang HH, McIntosh AR, Hasinoff BB et al (2000) B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 60:5862–5869PubMed
41.
42.
Walzog B, Gaehtgens P (2000) Adhesion molecules: the path to a new understanding of acute inflammation. News Physiol Sci 15:107–113PubMed
43.
Narita T, Kawakami-Kimura N, Kasai Y et al (1996) Induction of E-selectin expression on vascular endothelium by digestive system cancer cells. J Gastroenterol 31:299–301PubMedCrossRef
44.
Auguste P, Fallavollita L, Wang N et al (2007) The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 170:1781–1792PubMedPubMedCentralCrossRef
45.
Kannagi R, Izawa M, Koike T et al (2004) Carbohydratemediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95:377–384PubMedCrossRef
46.
Subramaniam V, Gardner H, Jothy S (2007) Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp Mol Pathol 83:341–346PubMedCrossRef
47.
Radinsky R, Ellis LM (1996) Molecular determinants in the biology of liver metastasis. Surg Oncol Clin N Am 5:215–229PubMed
48.
Mueller L, Goumas FA, Himpel S et al (2007) Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett 250:329–338PubMedCrossRef
49.
Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7(10):e47045PubMedPubMedCentralCrossRef
50.
Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322PubMedCrossRef
51.
Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86:1065–1073PubMedCrossRef
52.
53.
Adachi Y, Inomata M, Kakisako K et al (1999) Histopathologic characteristics of colorectal cancer with liver metastasis. Dis Colon Rectum 42:1053–1056PubMedCrossRef
54.
Talbot IC, Ritchie S, Leighton MH et al (1980) The clinical significance of invasion of veins by rectal cancer. Br J Surg 67:439–442PubMedCrossRef
55.
Wong SK, Jalaludin BB, Henderson CJ et al (2008) Direct tumor invasion in colon cancer: correlation with tumor spread and survival. Dis Colon Rectum 51:1331–1338PubMedCrossRef
56.
Cui YL, Li HK, Zhou HY, Zhang T, Li Q (2013) Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev 14(2):1003–1007PubMedCrossRef
57.
Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242–249PubMedCrossRef
58.
Ma J, Liu L, Che G et al (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112PubMedPubMedCentralCrossRef
59.
60.
Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A et al (2011) A human promyelocytic-like population is responsible for the immunosuppression mediated by myeloid-derived suppressor cells. Blood 118:2254–2265PubMedPubMedCentralCrossRef
61.
62.
Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest 123(4):1580–1589CrossRef
63.
Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M (2013) Tumor STAT1 transcription factor activity enhances breast tumor growth and immunosuppression mediated by myeloid-derived suppressor cells. J BiolChem 288(17):11676–11688
64.
Guo Q, Lv Z, Fu Q, Jiang C, Liu Y, Lai L et al (2012) IFN- gamma producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment. Int Immunopharmacol 12:425–432PubMedCrossRef
65.
Kusmartsev S, Nagaraj S, Gabrilovich DI (2005) Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 175:4583–4592PubMedPubMedCentralCrossRef
66.
Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172:989–999PubMedCrossRef
67.
Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24:301–305CrossRef
68.
Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr- 1 + CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRef
69.
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977–983PubMedCrossRef
70.
Simpson KD, Templeton DJ, Cross JV (2012) Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 189:5533–5540PubMedPubMedCentralCrossRef
71.
Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY et al (2011) Activated NKT cells and Nk cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 187:708–717PubMedPubMedCentralCrossRef
72.
Kerkar SP, Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72:3125–3130PubMedCrossRef
73.
Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenictherapy. Int Immunopharmacol 11:856–861PubMedCrossRef
74.
Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S et al (2010) Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A 107:13063–13068PubMedPubMedCentralCrossRef
75.
Lim SY, Gordon-Weeks AN, Zhao L, Tapmeier TT, Im JH, Cao Y, Beech J, Allen D, Smart S, Muschel RJ (2013) Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. Oncoimmunology 2(3):e23187PubMedPubMedCentralCrossRef
76.
Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell 13:23–35PubMedPubMedCentralCrossRef
77.
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR et al (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222–225PubMedPubMedCentralCrossRef
78.
Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin RA, Yu H, Reckamp KL (2013) Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One 8(5):e65121PubMedPubMedCentralCrossRef
79.
Yoshidome H, Kohno H, Shida T, Kimura F, Shimizu H, Ohtsuka M et al (2009) Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int J Oncol 34:923–930PubMedCrossRef
80.
Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K (2013) Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 8(2):e57114PubMedPubMedCentralCrossRef
81.
Teijeira A, Rouzaut A, Melero I (2013) Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes. Front Immunol 4:433PubMedPubMedCentralCrossRef
82.
Sakai N, Yoshidome H, Shida T, Kimura F, Shimizu H, Ohtsuka M, Takeuchi D, Sakakibara M, Miyazaki M (2012) CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis 29(2):101–110PubMedCrossRef
83.
Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761–1767PubMedCrossRef
84.
85.
Kim J, Takeuchi H, Lam ST et al (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744–2753PubMedCrossRef
86.
Miki J, Furusato B, Li H et al (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67:3153–3161PubMedCrossRef
87.
Lin EH, Hassan M, Li Y et al (2007) Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110:534–542PubMedCrossRef
88.
Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985–992PubMedCrossRef
89.
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMed
90.
Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y et al (2012) Regulatory T Cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20:946–955PubMedPubMedCentralCrossRef
91.
Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2009) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093–1102PubMedCrossRef
92.
Maker AV, Ito H, Mo Q, Qin L, DeMatteo RP, Blumgart LH, Fong Y, Maithel SK, Jarnagin WR, D’Angelica MI (2010) Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases. ASCO Meeting Abstr 28:10571
93.
Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Buchler MW et al (2008) Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 15:2310–2317PubMedCrossRef
94.
Qin JZ, Upadhyay V, Prabhakar B, Maker AV (2013) Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med 11:70PubMedPubMedCentralCrossRef
95.
Almeida AR et al (2010) CD4(+)CD25(+) Treg regulate the contribution of CD8(+) T-cell subsets in repopulation of the lymphopenic environment. Eur J Immunol 40:3478–3488PubMedCrossRef
96.
97.
98.
Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577–584PubMedCrossRef
99.
Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31:220–227PubMedPubMedCentralCrossRef
100.
Huang X, Zou Y, Lian L, Wu X, He X, He X, Wu X, Huang Y, Lan P (2013) Changes of T cells and cytokines TGF-β1 and IL-10 in mice during liver metastasis of colon carcinoma: implications for liver anti-tumor immunity. J Gastrointest Surg 17(7):1283–1291PubMedCrossRef
Metadata
Title
Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway
Authors
Alexandros Giakoustidis
Satvinder Mudan
Thorsten Hagemann
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 3/2015
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-014-0155-5

Other articles of this Issue 3/2015

Cancer Microenvironment 3/2015 Go to the issue

Original Paper

The Role of Mast Cells in Molding the Tumor Microenvironment

Original Article

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Original Paper

Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV

OriginalPaper

Preface

Original Article

Stroma as an Active Player in the Development of the Tumor Microenvironment

OriginalPaper

IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits